CAR T-cell intrinsic PD-1 checkpoint blockade: A two-in-one approach for solid tumor immunotherapy

CAR T-cell intrinsic PD-1 checkpoint blockade: A two-in-one approach for solid tumor immunotherapy

PD-L1/2 expression in solid tumors inhibits chimeric antigen receptor (CAR) T-cell efficacy. A PD-1 dominant negative receptor expressed in CAR T cells provides cell-intrinsic checkpoint blockade and augments antitumor efficacy. A combinatorial immunotherapeutic strategy of combining CAR T cells wit...

Full description

Bibliographic Details
Main Authors: Nan Chen, Aurore Morello, Zachary Tano, Prasad S. Adusumilli
Format: Article
Language:English
Published: Taylor & Francis Group 2017-02-01
Series:OncoImmunology
Subjects:
adoptive t-cell therapy
breast cancer
immunosuppression
lung cancer
mesothelioma
pd-1 blockade
tumor microenvironment
Online Access:http://dx.doi.org/10.1080/2162402X.2016.1273302
Description
Summary:PD-L1/2 expression in solid tumors inhibits chimeric antigen receptor (CAR) T-cell efficacy. A PD-1 dominant negative receptor expressed in CAR T cells provides cell-intrinsic checkpoint blockade and augments antitumor efficacy. A combinatorial immunotherapeutic strategy of combining CAR T cells with checkpoint blockade is a promising treatment approach for solid tumors.
ISSN:2162-402X

Similar Items